Esophageal Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of death from cancer. The two main subtypes of esophageal cancer, depending on the cell of origin, are squamous cell carcinoma and adenocarcinoma. Other uncommon forms of esophageal cancer include melanoma, lymphomas, sarcomas, and carcinoid tumors. Esophageal cancer is becoming more common everywhere. In some regions and populations, esophageal cancer is more prevalent than in others. In 2018, 570,000 people were expected to develop oesophageal cancer, accounting for 3.2 % of all cancer cases. For these conditions, endoscopic therapy is preferred, such as endoscopic mucosal resection, endoscopic submucosal dissection, and/or ablation.

Description

Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of death from cancer. The two main subtypes of esophageal cancer, depending on the cell of origin, are squamous cell carcinoma and adenocarcinoma. Other uncommon forms of esophageal cancer include melanoma, lymphomas, sarcomas, and carcinoid tumors. Esophageal cancer is becoming more common everywhere. In some regions and populations, esophageal cancer is more prevalent than in others. In 2018, 570,000 people were expected to develop oesophageal cancer, accounting for 3.2% of all cancer cases. For these conditions, endoscopic therapy is preferred, such as endoscopic mucosal resection, endoscopic submucosal dissection, and/or ablation.

Esophageal Cancer (Epidemiology)

Esophageal cancer is becoming more common everywhere in the world. Esophageal cancer is more prevalent in some regions and populations than others. In 2018, 570,000 people were expected to develop oesophageal cancer, which accounted for 3.2% of all cancer cases. Around the world, ESCC accounts for about 87% of esophageal malignancies while EAC makes up 11%. The highest age-standardized incidence rate was found in Eastern Asia (12.02 per 100,000), followed by Eastern and Southern Africa (8.03 and 7.04 per 100,000, respectively), and Northern Europe (5.05 per 100,000). The lowest rate was in Central America (0.98 points per 100,000). There were 56-fold differences in incidence rates between the countries with the highest rates that report data on both sexes (Malawi, Southeastern Africa: 18.7; Guinea, West Africa: 0.42). Notably, esophageal carcinoma is the most common cancer diagnosis in Malawi. China accounted for 49% of all esophageal cancer cases, with Asia as a whole accounting for 78% of all cases.

Esophageal Cancer -Current Market Size & Forecast Trends

The global market for esophageal cancer is projected to experience significant growth, with estimates indicating a market size of approximately USD 1.34 billion in 2023, expected to reach around USD 2.57 billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2024 to 2031. This growth is driven by increasing incidence rates of esophageal cancer, advancements in treatment options including chemotherapy, targeted therapies, and immunotherapies, as well as rising awareness of early detection methods. The market is also supported by a robust pipeline of innovative therapies and government initiatives aimed at improving patient outcomes.

North America is anticipated to dominate the market due to its advanced healthcare infrastructure and significant investments in cancer research, while the Asia-Pacific region is expected to exhibit rapid growth, attributed to improvements in healthcare facilities and access to essential services. The market landscape is evolving with a focus on personalized medicine and palliative care, enhancing the overall management of esophageal cancer. As new therapies continue to emerge and research progresses, the esophageal cancer market is well-positioned for continued expansion through 2035.

For these conditions, endoscopic therapy, such as endoscopic mucosal resection, endoscopic submucosal dissection, and/or ablation, is preferred. Transhiatal, transthoracic, or minimally invasive approaches may be used; gastric reconstruction is preferred; and feeding jejunostomy is preferred to gastrostomy for postoperative nutritional support in patients with extensive HGD or pT1a adenocarcinoma with nodular disease that cannot be adequately controlled by ER with or without ablation. Following R0 resection, postoperative fluoropyrimidine-based chemoradiation should be used to treat all adenocarcinoma patients with Tis, T3-T4 tumors, node-positive T1-T2 tumors, and selected patients with T2, N0 tumors with high-risk features. Chemotherapy is advised following R0 resection for all adenocarcinoma patients, regardless of nodal status. Preoperative and definitive chemoradiation should both use fluoropyrimidine- or taxane-based regimens, and definitive chemoradiation should be administered to all T4b (unresectable) tumors. Trastuzumab should be added to first-line chemotherapy (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents) for patients with HER2-overexpressing advanced or metastatic adenocarcinoma (tumor immunohistochemistry [IHC] score of 3+ or 2+ with the evidence of HER2 amplification by fluorescent in situ hybridization [FISH]). Ramucirumab was approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of patients with advanced esophagogastric junction (EGJ) adenocarcinoma that was either refractory to or progressed after receiving platinum- or fluoropyrimidine-based chemotherapy.

Report Highlights

Esophageal Cancer - Current Market Trends

Esophageal Cancer - Current & Forecasted Cases across the G8 Countries

Esophageal Cancer - Market Opportunities and Sales Potential for Agents

Esophageal Cancer - Patient-based Market Forecast to 2035

Esophageal Cancer - Untapped Business Opportunities

Esophageal Cancer - Product Positioning Vis-a-vis Competitors' Products

Esophageal Cancer - KOLs Insight